55 The SURMOUNT Program includes four global phase 3, randomized, placebo-controlled clinical trials with tirzepatide administered subcutaneously once weekly in conjunction with lifestyle intervention.47, 48, 49 There was a substantial degree of weight reduction with 10 mg and 15 mg doses of 18.420.9% in persons with obesity or preobesity (without diabetes), with improvements in cardiometabolic risk factors (Table 2).47, 48, 49 Lower bodyweight reductions of 12.8% and 14.7% with 10 mg and 15 mg doses of tirzepatide, respectively, were observed in persons with preobesity or obesity and T2DM
Neuroplasticity, memory Orexin-A ~20 min Hypothalamic neuropeptide
doi: 10.1089/jmf.2018.4255 72
Atorvastatin-modified dendritic cells in vitro ameliorate experimental autoimmune myasthenia gravis by up-regulated Treg cells and shifted Th1/Th17 to Th2 cytokines
Blake CFF, Johnson LN, Mair GA, North ACT, Phillips DC, Sarma VR